Tandem Diabetes Care TNDM Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's additional paid-in capital?
- Tandem Diabetes Care (TNDM) reported additional paid-in capital of $1.4B in Q1 2026.
- How has Tandem Diabetes Care's additional paid-in capital changed year-over-year?
- Tandem Diabetes Care's additional paid-in capital increased by 5.0% year-over-year, from $1.33B to $1.4B.
- What is the long-term trend for Tandem Diabetes Care's additional paid-in capital?
- Over 5 years (2020 to 2025), Tandem Diabetes Care's additional paid-in capital has grown at a 6.5% compound annual growth rate (CAGR), from $1.03B to $1.4B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.